EUVIMEDEUVIMED entdecken
Crossref

Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge

Ansgar Santel, Jörg Kaufmann

Nucleic Acid Insights · 2024

DOI: 10.18609/nai.2024.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Insights, 2024. Verfasst von Ansgar Santel und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic catapulted mRNA into the spotlight—but what wider impacts did this success have on the field? David McCall, Senior Editor, Nucleic Acid Insights, speaks to Ansgar Santel, CEO and Jörg Kaufmann, CSO, of Pantherna Therapeutics about the latest developments in the mRNA–LNP space, tackling myths and safety concerns surrounding cationic lipids, and Pantherna’s approach to solving the issue of moving beyond hepatocyte targeting.

Zitieren

APA

Santel, A., & Kaufmann, J. (2024). Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge. Nucleic Acid Insights. https://doi.org/10.18609/nai.2024.022

Vancouver

Santel A, Kaufmann J. Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge. Nucleic Acid Insights. 2024. doi:10.18609/nai.2024.022

BibTeX
@article{Santel2024,
  author = {Santel, Ansgar and Kaufmann, Jörg},
  title = {Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge},
  journal = {Nucleic Acid Insights},
  year = {2024},
  doi = {10.18609/nai.2024.022}
}
Kostenlos starten →